Study to Assess Cancer Patients' Satisfaction With Hospital Quality of Care
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Questionnaires may help determine cancer patients' satisfaction with the quality of care they received in the hospital.
PURPOSE: Clinical trial to determine the effectiveness of questionnaires in assessing cancer patients' satisfaction with the quality of care they received in the hospital.
| Condition | Intervention |
|---|---|
|
Unspecified Adult Solid Tumor, Protocol Specific |
Other: quality-of-life assessment |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | An International Field-Testing Study Of The Reliability And Validity Of A Patient Satisfaction Module (QLQ-SAT32) Assessing Cancer Patients' Perception Of The Quality Of Care Received Within The Hospital |
| Enrollment: | 795 |
| Study Start Date: | May 2002 |
| Study Completion Date: | March 2005 |
| Primary Completion Date: | June 2004 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
discharged cancer patients
patients discharged from a surgery or medical ward of oncology institutes in Belgium, France, Germany, Italy, Poland, Spain, Sweden, Taiwan and United Kingdom (as part of a larger psychometric validation study) were asked to rate there level of satisfaction, using the EORTC QLQ-SAT32.
|
Other: quality-of-life assessment
QLQ-C30 SAT32
Other Name: QoL
|
Detailed Description:
OBJECTIVES:
- Determine the scale structure, reliability, and validity of the QLQ-SAT32 patient satisfaction module in assessing the perception of the quality of care received in hospitals by patients with cancer.
- Determine the success of the QLQ-SAT32 patient satisfaction module when used with the QLQ-C30 core quality of life questionnaire, in terms of expanding on quality of life evaluation or providing information on treatment acceptability or preference of these patients.
OUTLINE: This is a descriptive, multicenter study. Patients are stratified according to age (18 to 49 vs 50 and over) and the cancer therapy received in hospital (surgery vs chemotherapy).
Patients in all strata receive the QLQ-SAT32 and QLQ-C30 questionnaires, a debriefing questionnaire, and the Oberst patient satisfaction visual analog scale prior to hospital discharge. Patients complete the materials at home within 7 days of discharge. A group of 100 patients have a repeat QLQ-SAT32 module mailed to them to be completed within 7 days of receipt of first questionnaire.
PROJECTED ACCRUAL: A total of 640-768 patients (160-192 per stratum) will be accrued for this study.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
cancer patients discharged from a surgery or medical ward of oncology institute.
DISEASE CHARACTERISTICS:
- Histologically confirmed cancer
- Hospitalization of at least 3 days
- No clinical evidence of brain metastases
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
Other
- No psychological, familial, sociological, or geographical condition that would preclude study
- Able to understand the language of the questionnaire
- Mentally fit to complete a questionnaire
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Prior chemotherapy allowed
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Prior surgery for cancer allowed
Other
- No concurrent participation in other quality of life studies that would preclude this study
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00045019
| Belgium | |
| Institut Jules Bordet | |
| Brussels, Belgium, 1000 | |
| France | |
| Institut Bergonie | |
| Bordeaux, France, 33076 | |
| Centre Regional Francois Baclesse | |
| Caen, France, 14076 | |
| Institut Curie - Section Medicale | |
| Paris, France, 75231 | |
| Centre Paul Strauss | |
| Strasbourg, France, 67085 | |
| Centre Alexis Vautrin | |
| Vandoeuvre-les-Nancy, France, 54511 | |
| Institut Gustave Roussy | |
| Villejuif, France, F-94805 | |
| Spain | |
| Hospital De Navarra | |
| Pamplona, Spain, 31008 | |
| Sweden | |
| Sahlgrenska University Hospital | |
| Gothenburg, Sweden, S-413 45 | |
| Uppsala University Hospital | |
| Uppsala, Sweden, S-75183 | |
| United Kingdom | |
| Bristol Royal Infirmary | |
| Bristol, United Kingdom, BS2 8HW | |
| Study Chair: | Anne Bredart | Institut Curie |
More Information
Additional Information:
No publications provided
| Responsible Party: | European Organisation for Research and Treatment of Cancer - EORTC |
| ClinicalTrials.gov Identifier: | NCT00045019 History of Changes |
| Other Study ID Numbers: | EORTC-15012, EORTC-15012 |
| Study First Received: | September 6, 2002 |
| Last Updated: | August 24, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
|
unspecified adult solid tumor, protocol specific |
ClinicalTrials.gov processed this record on March 03, 2015